Evidence map›Paper›PMID 29049729›Full record

ArticleInvestigative ophthalmology & visual science2017

Myocilin Regulates Metalloprotease 2 Activity Through Interaction With TIMP3.

Myung Kuk Joe, Raquel L Lieberman, Naoki Nakaya, Stanislav I Tomarev

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Clusterin, other extracellular chaperones, and eye disease.Progress in retinal and eye research · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Another Piece of the Puzzle: MYOC and Myocilin Glaucoma.Investigative ophthalmology & visual science · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Myung Kuk JoeSection of Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Raquel L LiebermanSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia, United States.
Naoki NakayaSection of Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Stanislav I TomarevSection of Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
National Institutes of Health · USGeorgia Institute of Technology · USNational Eye Institute · US

Funding

Molecular Mechanisms Of GlaucomaZIAEY000318 · NEI · NATIONAL EYE INSTITUTE · PI TOMAREV, STANISLAV I · 2009 to 2025
$18.9M
Request for Supplement to Promote Diversity in Health Related ResearchR01EY021205 · NEI · GEORGIA INSTITUTE OF TECHNOLOGY · PI Raquel L Lieberman · 2011 to 2026
$6.8M
NEI NIH HHS R01 EY021205
6 · The paper itself

Abstract

Purpose: To elucidate functions of wild-type myocilin, a secreted glycoprotein associated with glaucoma. Methods: Lysates of mouse eyes were used for immunoprecipitation with affinity-purified antibodies against mouse myocilin. Shotgun proteomic analysis was used for the identification of proteins interacting with myocilin. Colocalization of myocilin and tissue inhibitor of metalloproteinases 3 (TIMP3) in different eye structures was investigated by a multiplex fluorescent in situ hybridization and immunofluorescent labeling with subsequent confocal microscopy. Matrix metalloproteinase 2 (MMP2) activity assay was used to test effects of myocilin on TIMP3 inhibitory action. Results: TIMP3 was identified by a shotgun proteomic analysis as a protein that was coimmunoprecipitated with myocilin from eye lysates of wild-type and transgenic mice expressing elevated levels of mouse myocilin but not from lysates of transgenic mice expressing mutated mouse myocilin. Interaction of myocilin and TIMP3 was confirmed by coimmunoprecipitation of myocilin and TIMP3 from HEK293 cells transiently transfected with cDNAs encoding these proteins. The olfactomedin domain of myocilin is essential for interaction with TIMP3. In the eye, the main sites of myocilin and TIMP3 colocalization are the trabecular meshwork, sclera, and choroid. Using purified proteins, it has been shown that myocilin markedly enhanced the inhibitory activity of TIMP3 toward MMP2. Conclusions: Myocilin may serve as a modulator of TIMP3 activity via interactions with the myocilin olfactomedin domain. Our data imply that in the case of MYOCILIN null or some glaucoma-causing mutations, inhibitory activity of TIMP3 toward MMP2 might be reduced, mimicking deleterious mutations in the TIMP3 gene.

Indexed as

AnimalsBlotting, WesternCiliary BodyCytoskeletal ProteinsEye ProteinsFemaleFluorescent Antibody Technique, IndirectGene ExpressionGlycoproteinsHEK293 CellsHep G2 CellsHumansImmunoprecipitationIn Situ Hybridization, FluorescenceMaleMatrix Metalloproteinase 2Cytoskeletal ProteinsEye ProteinsGlycoproteinsMatrix Metalloproteinase 2Mmp2 protein, mouseMyocilinRNA, MessengerTissue Inhibitor of Metalloproteinase-3

Identifiers

PMID29049729
PMCPMC5644706
OpenAlexW2749787717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.